Look back at pharma news in the week to November 13, 2020

13 November 2020

In case anyone missed it, the main news this week was Pfizer and BioNTech announcing that a Phase III trial of their COVID-19 vaccine had shown more than 90% efficacy in a Phase III trial. Eli Lilly also made a major advance in COVID-19, albeit with a treatment rather than a vaccine. Elsewhere, there was analysis of the latest aducanumab update in Alzheimer’s, along with some important data for Amgen and AstraZeneca’s asthma candidate tezepelumab.

Cautious positivity

Writing for Evaluate Vantage, Amy Brown stressed that this was “only the first hurdle” for Pfizer and BioNTech’s mRNA vaccine candidate BNT162b2, amid hopes that it could bring an end to the pandemic.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK